Middle East and Africa Cerebrospinal Fluid Management Market

The Middle East and Africa cerebrospinal fluid management market is expected to reach US$ 61.68 million by 2028 from US$ 48.08 million in 2021; it is estimated to grow at a CAGR of 3.6% from 2021 to 2028.

The growth of the market is attributed to the increasing incidence of cerebrospinal fluid (CSF) leaks and growing developments for CSF management products. However, the risk associated with CSF shunts hinders the market growth.

The never-ending technological developments are the unstoppable trend for the growth of CSF management market. The risk of diagnosing and treatment failure, limited control options, and complications have offered various opportunities for the product developers. Rising advancements in technology have introduced the concept of “smart shunt” that could offer hi-tech control, diagnosis, and communication-based shunts or implants. It is anticipated that designed smart shunts can control CSF drainage based on feedback from one or more measured conditions. Additionally, researchers expect that smart shunts have the potential to offer sophisticated control over mechanical shunts—data with respect to shunt malfunction. It is further expected to reduce the risk of shunt obstructions and eventually reduce the risk of failures.

Late-stage development companies operating in the market are demanding experimental results to seek approvals and commercialize the smart shunts. The primary focus is on shunts designed to assess ICP noninvasively in the physician’s office through an implanted pressure sensor and noninvasive assessment of CSF flow in the clinical settings. These on-demand sensing systems will be a significantly advanced supplement to existing mechanical valves.

The growing demand for better treatments has resulted in various product developments, resulting in the Middle East and Africa cerebrospinal fluid management market growth. For instance, in July 2018, FDA granted breakthrough device designation to F. Hoffmann-La Roche Ltd for its Elecsys ß-Amyloid (1-42) CSF and Elecsys Phospho-Tau (181P) CSF. The products are used as in-vitro diagnostic immunoassays to measure ß-Amyloid (1-42) and Phospho-Tau concentrations in CSF among adults with cognitive impairment. They are evaluated for Alzheimer’s disease (AD) and other causes of dementia.

The COVID-19 pandemic is causing turbulence to the economies of Middle East. For instance, countries such as Syria, Libya, and Yemen are suffering violent conflicts and cannot implement robust public health measures. A sudden drop in domestic and external demand for goods and products, especially crude oil, and halted production due to labor shortage are major impacts observed in the region.

Furthermore, with widespread of the pandemic, various conferences organized by neurological societies and associations have been postponed or cancelled. The COVID-19 pandemic is further expected to stretch resources of already fragile neurosurgical systems in developing countries.

Middle East and Africa Cerebrospinal Fluid Management Market Revenue and Forecast to 2028 (US$ Mn)

Middle East and Africa Cerebrospinal Fluid Management Strategic Insights

Strategic insights for the Middle East and Africa Cerebrospinal Fluid Management provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East and Africa Cerebrospinal Fluid Management Report Scope

Middle East and Africa Cerebrospinal Fluid Management Regional Insights

The geographic scope of the Middle East and Africa Cerebrospinal Fluid Management refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

MIDDLE EAST AND AFRICA CEREBROSPINAL FLUID MANAGEMENT MARKET SEGMENTATION

By Product

• CSF shunts
• CSF drainage systems

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Neurological Centers

By Country

• Saudi Arabia
• South Africa
• UAE
• Rest of MEA

Company Profiles

• Medtronic
• Integra Life Sciences Corporation
• B. Braun Melsungen AG
• DePuy Synthes
• Natus Medical Incorporated
• Spiegelberg GmbH & Co. KG